Mid‐term efficacy and safety of adalimumab in refractory pediatric uveitis : A retrospective monocentric study

Purpose Evaluate the mid‐term efficacy and safety of adalimumab in the pediatric population with severe uveitis. Methods We retrospectively analysed 18 children with severe uveitis, who were treated with adalimumab (20 or 40 mg every two weeks) when the previous immunosuppressive therapy has been in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Acta ophthalmologica (Oxford, England) England), 2013-08, Vol.91 (s252), p.0-0
1. Verfasser: PENAUD, B
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose Evaluate the mid‐term efficacy and safety of adalimumab in the pediatric population with severe uveitis. Methods We retrospectively analysed 18 children with severe uveitis, who were treated with adalimumab (20 or 40 mg every two weeks) when the previous immunosuppressive therapy has been ineffective. It consisted of systemic corticosteroids (n=18), methotrexate (n=18), azathioprine (n=8), infliximab (n=6), etanercept (n=6), interferon‐alpla (n=1). Primary outcome was to assess laser flare photometry values after adalimumab therapy compared with baseline. Clinical features (SUN criteria, macular edema and papillitis), oral prednisone threshold, visual acuity, side effects and complications of treatment were also considered. Results Median age was 13.1 years (range 6‐20.8),sex ratio (F/M) was 3. Median duration before adalimumab therapy was 82.6 months (range 16‐262). The mean follow‐up was 35.5 months (range 23‐63) and the final median laser flare photometry value was significantly reduced from 149.5 ph/ms (range 24‐335) to 81.3 ph/ms (range 4‐224) p
ISSN:1755-375X
1755-3768
DOI:10.1111/j.1755-3768.2013.3454.x